Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 8Carcinoma, Transitional Cell 8Breast Neoplasms 7Lung Neoplasms 6Ovarian Neoplasms 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Testicular Neoplasms 3Stomach Neoplasms 3Sarcoma 3Melanoma 3Fallopian Tube Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Oropharyngeal Neoplasms 2Neoplasms, Unknown Primary 2Mouth Neoplasms 2Lymphoma, Non-Hodgkin 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Teratoma, Testicular 1

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Urothelial Carcinoma × Taxes × Genitourinary × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡